FDA OKs Merck’s Keytruda for Hodgkin lymphoma, a first in blood cancer
Merck has racked up another FDA approval for Keytruda, this time for classical Hodgkin lymphoma, marking the PD-1 blocker’s first green-light for use in liquid tumors.
Regulators handed out the OK for patients who had already failed at least three therapies.
The agency based this approval on the data Merck collected in 210 patients from the KEYNOTE-087 trial, which demonstrated an overall response rate of 69%, with a complete remission rate — no detectable cancer — of 22% and a partial remission rate of 47%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.